What is the preferred sequence of systemic therapy in a patient with endocrine resistant HR+ metastatic breast cancer?
The patient previously received endocrine therapy alone and in combination with CDK 4/6 inhibitor. She does not have any targetable mutations on NGS. What factors would impact your treatment decision?
Answer from: Medical Oncologist at Community Practice
Several factors can affect the next line of therapy in my view like disease free interval (DFI) before the patient developed metastatic disease, duration of response (if any) to prior endocrine with/without CDK4/6i, disease burden, patient's performance status and competing comorbidity.
If the pati...
Sign in or Register to read more